Delivery Order 75N91019D00020-75N91022F00002
Ended Awarded Last action
- Contract number
- 75N91022F00002
- Awardee
-
University Of Oklahoma UEI GY8NMUZQXVS7 Part of University Of Oklahoma
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,435,788
Award facts
- Opportunity
-
- TORFP2022E04 Solicitation number
- Contract value 100% obligated
- $1,435,788.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 2 offers Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Oklahoma City, OK 73104, USA
- Legislative mandates
-
- Walsh-Healey Public Contracts Act FAR subpart 22.6
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Change Order | $389,694 | |
| Original award | $1,046,094 |
About this award
This is a delivery order issued under the "PREVENT Preclinical Drug Development Program (PREVENT)" indefinite-delivery, indefinite-quantity (IDIQ) contract, awarded by the National Cancer Institute (NCI) to the University of Oklahoma Univ Of Oklahoma Health Sciences Center Division.
The $1,435,788.00 firm fixed-price contract is for a project titled "BLADDER CANCER CHEMOPREVENTION USING THE ANDROGEN RECEPTOR INHIBITOR APALUTAMIDE", with a completion date of February 4, 2026. The contract is not set aside for any specific business size or type.
The University of Oklahoma, a state-controlled institution of higher learning, is the prime contractor. As the awardee, the University of Oklahoma will likely provide medical research, healthcare, and education services in support of the bladder cancer chemoprevention project. The National Cancer Institute, a civilian agency within the U.S. Department of Health and Human Services, is the funding agency for this contract.
Quick answers
Who was awarded contract 75N91022F00002?
75N91022F00002 was awarded to University Of Oklahoma by National Cancer Institute (National Institutes of Health) on August 5, 2022.
How much is contract 75N91022F00002 worth?
The government has obligated $1,435,788 on 75N91022F00002.
Is contract 75N91022F00002 an order under another contract?
Yes. 75N91022F00002 is a delivery order under 75N91019D00020, an indefinite delivery contract, on PREVENT Preclinical Drug Development Program (PREVENT).
Was contract 75N91022F00002 competed?
The extent of competition for 75N91022F00002 was full and open competition. The government received 2 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award